News

GLM101 is the first disease-modifying therapeutic in development to treat PMM2-CDG, the most common congenital disorder of glycosylation Data from the ongoing Phase 2 open-label study of GLM101 provide clinical proof of concept, showing improvement in ataxia, a key burden of disease in PMM2-CDG Funding will support advancement of GLM101 into a randomized, placebo-controlled Phase…

2024-03-04 Glycomine Announces Encouraging Efficacy Data from Ongoing Phase 2 Clinical Study in PMM2-CDG Initial data from adult patients with PMM2-CDG showed promising evidence of clinical benefit with GLM101 Notable improvements were seen in ataxia, one of the most frequent disease-associated clinical symptoms Data from this study provides key insights into future planned clinical trials…

SAN CARLOS, Calif., January 9, 2023 – Glycomine, Inc., a clinical-stage biotechnology company focused on developing new therapies for orphan diseases, today announced that the first patient has been dosed in a multi-center open-label Phase 2 study (ClinicalTrials.gov Identifier: NCT05549219) of GLM101, a targeted mannose-1-phosphate replacement therapy, in adult patients with phosphomannomutase 2-congenital disorder of glycosylation…

DECEMBER 11, 2023 SAN CARLOS, Calif., December 11, 2023 – Glycomine, Inc., a clinical-stage biotechnology company focused on developing new therapies for orphan diseases, announced the first pediatric patient has been dosed in a multi-center open-label Phase 2 study of GLM101, a mannose-1-phosphate replacement therapy, in patients with phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG). “The initiation of dosing…

OCTOBER 12, 2023 SAN CARLOS, Calif., October 12, 2023 – Glycomine, Inc., a clinical-stage biotechnology company focused on developing new therapies for serious orphan diseases, announced the appointment of Rose Marino, M.D. as Chief Medical Officer. Dr. Marino has more than 20 years of collective experience in academic medicine and clinical development in the pharmaceutical industry,…

October 10, 2024 SAN CARLOS, Calif., October 10, 2024 – Glycomine, Inc., a clinical-stage biotechnology company focused on developing new therapies for serious unserved orphan diseases, today announced the appointment of Joshua Grass as Chairperson of the Board. Mr. Grass succeeds Christopher Starr, Ph.D., who will continue to support the company as a scientific and clinical…